Original BioMedicals Co., Ltd.

Original BioMedicals (OBM) has two main technologies : one is Chelating-Complex Micelle (CCM), composed of polyethylene glycol micelle with a metal moiety at the center which interacts – chelates-with blocking copolymers to form reversible bonds. CCM prolongs the half-life of the drug and can be tuned, by changing the diameters of the micelles, to modify the distribution of the micelle-drug complex in the body. These formulation modifications also increase their effective half-life while reducing potentially adverse effects. Another one is Trigger Release Technology, further utilizes the functions of the chelating agent within the micelle and allows for a controlled release rate and focused release location of drug. TRT creates innovative strategies for use of currently approved drugs that are safer and more effective than traditional formulations. The key to TRT is the ability to release drug by reversing the metal, drug interaction within CCM using common metal chelators delivered to specific site in the body. OBM's vision is to using a collaborative research and professional environment, bring creative scientists and clinicians together to create novel formulations and innovative drug products that will improve the health and lives of people both locally and globally.